Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder-Reference-Cited by-同舟云学术

Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder

Published:2020-01 Issue:2 Volume:21 Page:111-123
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Zastrozhin Michael S¹²^ORCID,Skryabin Valentin Y¹,Torrado Marco³,Petrovna Anastasiya¹,Sorokin Alexander S¹,Grishina Elena A²,Ryzhikova Kristina A²,Bedina Inessa A¹,Buzik Oleg Z¹,Chumakov Egor M⁴⁵,Savchenko Ludmila M²,Brun Evgeny A¹²,Sychev Dmitry A²

Affiliation:

1. Moscow Research & Practical Centre on Addictions of the Moscow Department of Healthcare, 37/1 Lyublinskaya Street, Moscow 109390, Russian Federation

2. Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, 2/1 Barrikadnaya Street, Moscow 123995, Russian Federation

3. University of Lisbon, Faculty of Medicine, ISAMB (Instituto de Saúde Ambiental) venida Professor Egas Moniz (Edifício comum ao Hospital de Santa Maria), 1649-028 Lisboa, Portugal

4. Saint-Petersburg State University, Department of Psychiatry & Addictions, Saint-Petersburg, Russian Federation

5. Saint-Petersburg Psychiatric Hospital No. 1 named after PP Kaschenko, Day In-Patient Department, Saint-Petersburg, Russian Federation

Abstract

Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: ( CYP2C19*1/*1) 2.00 [1.00; 2.00), ( CYP2C19*1/*2) 7.00 (7.00; 7.00), ( CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2019-0019

Reference43 articles.

1. Substance-dependent patients with and without social anxiety disorder: Occurrence and clinical differences

2. Multiple Drug Use and Psychiatric Comorbidity in Patients Admitted to the Hospital With Severe Benzodiazepine Dependence

3. Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study

4. Alterations in Pharmacodynamics of Anxiolytics in Abstinent Alcoholic Men: Subjective Responses, Abuse Liability, and Electroencephalographic Effects of Alprazolam, Diazepam, and Buspirone

5. Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MiRNA Differences Related to Treatment-Resistant Schizophrenia;International Journal of Molecular Sciences;2023-01-18

2. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder;The Pharmacogenomics Journal;2021-02-19

3. Problems of integrating medical science, image and practical health care: focus on personalized medicine;Pharmacogenetics and Pharmacogenomics;2020-12-28